Previous 10 | Next 10 |
2023-06-26 08:58:49 ET Wave Life Sciences ( NASDAQ: WVE ) said on Monday that it had joined the Russell 2000 and Russell 3000 indexes as a part of the annual reconstitution, effective after the U.S. market opens on June 26. Press Release For further details...
CAMBRIDGE, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that the company has been added to the small-cap Russell 200...
2023-06-21 10:00:50 ET Summary Recent developments have created some uncertainties for Wave Life Sciences in its clinical programs. The discontinuation of the WVE-004 program corroborates a revised rating of hold on the company in my view. Investors should watch for updates on...
2023-05-23 08:12:07 ET Wave Life Sciences ( NASDAQ: WVE ) announced Tuesday it decided to halt further development of its neurology candidate WVE-004 after a failure in a Phase 1/2 trial for certain patients with amyotrophic lateral sclerosis (ALS) and dementia. WVE shares fell ~2...
Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated WVE-004 did not show clinical benefit compared with placebo; additionally, poly(GP) reductions did not correlate with cl...
Presentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD) which is designed to restore healthy, wild-type AAT protein Best-in-class exon skipping clinical data f...
2023-05-03 13:48:06 ET Wave Life Sciences Ltd. (WVE) Q1 2023 Earnings Conference Call May 03, 2023, 08:30 AM ET Company Participants Kate Rausch - VP, IR and Corporate Affairs Paul Bolno - President and CEO Anne-Marie Li-Kwai-Cheung - Chief Development Officer ...
2023-05-03 07:55:34 ET Wave Life Sciences press release ( NASDAQ: WVE ): Q1 GAAP EPS of -$0.27 misses by $0.23 . Revenue of $12.93M (+638.9% Y/Y) misses by $25.67M . As of March 31, 2023, Wave had $207.6 million in cash and cash equivalents, as compared to $88....
Emerging leader in RNA medicines with multi-modal discovery and development platform and first-in-class RNA editing programs Rapidly advancing toward 2023 CTA submissions and first-in-human study for WVE-006, the industry’s first RNA editing clinical candidate Planning fo...
2023-05-02 13:14:01 ET Wave Life Sciences ( NASDAQ: WVE ) is scheduled to announce Q1 earnings results on Wednesday, May 3rd, before market open. The consensus EPS Estimate is -$0.04 (+93.5% Y/Y) and the consensus Revenue Estimate is $38.6M (+2105.7% Y/Y). Over the las...
News, Short Squeeze, Breakout and More Instantly...
Wave Life Sciences Ltd. Company Name:
WVE Stock Symbol:
NASDAQ Market:
Wave Life Sciences Ltd. Website:
2024-07-17 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated profile achieved in 30 mg multidose cohort ...
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for obesity designed to induce fat burning and preserve muscle mass with once or twice-annual sub...